HighVista Strategies’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

HighVista Strategies’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-76,021	Closed	-$2.92M	–	169
2023 Q2	$2.92M	Buy	76,021 +26,526	+54%	+$681K	1.34%	20
2023 Q1	$1.15M	Hold	49,495	–	–	0.93%	31
2022 Q4	$1.3M	Sell	49,495 -34,056	-41%	-$754K	0.77%	34
2022 Q3	$1.64M	Buy	83,551 +32,717	+64%	+$656K	0.94%	33
2022 Q2	$889K	Sell	50,834 -16,943	-25%	-$266K	0.54%	41
2022 Q1	$1.11M	Buy	+67,777	New	+$922K	0.71%	31

HighVista Strategies's KDNY Position: Q3 2023 in Review

HighVista Strategies sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 76,021 shares — an estimated $2.92M sold.

HighVista Strategies first reported a position in KDNY in Q1 2022 and held it in 6 quarters. The position peaked at $2.92M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

HighVista Strategies reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
HighVista Strategies sold 76,021 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.92M.
HighVista Strategies first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
HighVista Strategies's Chinook Therapeutics, Inc. Common Stock position peaked at $2.92M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.